Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis
Bacterial vaginosis affects nearly 20 million women in the U.S. every year SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling
View HTML
Toggle Summary Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018.
View HTML
Toggle Summary Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast
SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018 , to provide a corporate update and
View HTML
Toggle Summary Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference
SAN DIEGO , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair , Chief Business Officer, will present at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October
View HTML
Toggle Summary Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th
SAN DIEGO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring (IVR) technologies at the Partnership
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum
SAN DIEGO , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will present at the 2018 BIO Investor Forum on Wednesday, October 17, 2018
View HTML
Toggle Summary Greg Matz Joins Daré Bioscience Board of Directors
SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Greg Matz to its board of directors. Most recently, Mr. Matz served as the Senior Vice President and Chief Financial Officer
View HTML